Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update.

[1]  Ja Hwang,et al.  Comparisons between different anti-osteoporosis medications on postfracture mortality: A population-based study. , 2022, The Journal of clinical endocrinology and metabolism.

[2]  S. Cummings,et al.  Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Ja Hwang,et al.  The Impact of Various Anti‐Osteoporosis Drugs on All‐Cause Mortality After Hip Fractures: A Nationwide Population Study , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  H. Ou,et al.  Reduced All‐Cause Mortality With Bisphosphonates Among Post‐Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review , 2022, Clinical pharmacology and therapeutics.

[5]  L. Chien,et al.  Incidence of different types of subsequent fractures and related mortality in Taiwan , 2022, Archives of Osteoporosis.

[6]  Yin-Fan Chang,et al.  The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study , 2022, Aging.

[7]  T. Lu,et al.  Validation of the Taiwan FRAX® calculator for the prediction of fracture risk , 2022, Archives of Osteoporosis.

[8]  T. Cheng,et al.  Simple Self-Assessment Tool to Predict Osteoporosis in Taiwanese Men , 2021, Frontiers in Medicine.

[9]  Chih-Hsing Wu,et al.  Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study. , 2021, Bone.

[10]  T. Lu,et al.  The effects of falls on the prediction of osteoporotic fractures: epidemiological cohort study , 2021, Archives of Osteoporosis.

[11]  F. Hsiao,et al.  Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients: A population‐based cohort study , 2021, Journal of internal medicine.

[12]  S. Goldstein.  Selective estrogen receptor modulators and bone health , 2021, Climacteric : the journal of the International Menopause Society.

[13]  Rong-Sen Yang,et al.  Real-world cost-effectiveness analysis of the fracture liaison services model of care for hip fracture in Taiwan. , 2021, Journal of the Formosan Medical Association = Taiwan yi zhi.

[14]  K. Tsai,et al.  One-year outcomes of an osteoporosis liaison services program initiated within a healthcare system , 2021, Osteoporosis International.

[15]  M. Hiligsmann,et al.  The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis , 2021, Osteoporosis International.

[16]  Erik J. Geiger,et al.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. , 2020, The New England journal of medicine.

[17]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[18]  L. Peng,et al.  Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. , 2020, Journal of the American Medical Directors Association.

[19]  D. Bennett,et al.  Vitamin D and Calcium for the Prevention of Fracture , 2019, JAMA network open.

[20]  T. Cheng,et al.  The role of bone mineral density in therapeutic decision-making using the Fracture Risk Assessment Tool (FRAX): a sub-study of the Taiwan OsteoPorosis Survey (TOPS) , 2019, Archives of Osteoporosis.

[21]  B. Zemel,et al.  Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Periprosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. , 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[22]  C.-H. Yang,et al.  Revisit three “I” model: a novel five “I” model of fracture liaison service , 2019, Osteoporosis International.

[23]  K. Tsai,et al.  Fracture types affect clinical outcomes of patients managed within the fracture liaison and osteoporosis medication management services , 2019, Scientific Reports.

[24]  C. Cooper,et al.  Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. , 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[25]  René Rizzoli,et al.  Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.

[26]  Ting-Shuo Huang,et al.  Secular trends in incidence of osteoporosis in Taiwan: A nationwide population-based study , 2018, Biomedical journal.

[27]  C. Niu,et al.  The development of Taiwan Fracture Liaison Service network , 2018, Osteoporosis and sarcopenia.

[28]  Sonal Singh,et al.  Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. , 2018, Bone.

[29]  K. Tsai,et al.  The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects , 2018, PloS one.

[30]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2018, Osteoporosis International.

[31]  Sonia M. Thomas,et al.  Comparisons of Interventions for Preventing Falls in Older Adults: A Systematic Review and Meta-analysis , 2017, JAMA.

[32]  Raveendhara R. Bannuru,et al.  2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis , 2017, Arthritis & rheumatology.

[33]  E. McCloskey,et al.  Establishing and evaluating FRAX® probability thresholds in Taiwan. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[34]  Chung-Yuan Hsu,et al.  Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid , 2017, Medicine.

[35]  W. Chie,et al.  Trends in hip fracture rates in Taiwan: a nationwide study from 1996 to 2010 , 2017, Osteoporosis International.

[36]  T. Fu,et al.  Secular trends in incidence and recurrence rates of hip fracture: a nationwide population-based study , 2016, Osteoporosis International.

[37]  P. Kuo,et al.  Effects of Age and Body Mass Index on Thoracolumbar Spine X-Ray for Diagnosing Osteoporosis in Elderly Women: Tianliao Old People (TOP) Study 07 , 2016, PloS one.

[38]  Yi-Yin Lin,et al.  Aging in Taiwan: Building a Society for Active Aging and Aging in Place. , 2016, The Gerontologist.

[39]  W. Leslie,et al.  Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD. , 2015, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[40]  Chung-Yuan Hsu,et al.  Development and Validation of an Osteoporosis Self-Assessment Tool for Taiwan (OSTAi) Postmenopausal Women-A Sub-Study of the Taiwan OsteoPorosis Survey (TOPS) , 2015, PloS one.

[41]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[42]  K. Tsai,et al.  The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. , 2014, The Journal of clinical endocrinology and metabolism.

[43]  Y. Kao Yang,et al.  Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population , 2014, Osteoporosis International.

[44]  J. Kanis,et al.  Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[45]  Hsi-Chin Wu,et al.  Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. , 2013, Bone.

[46]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[47]  C. Cooper,et al.  Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[48]  J. Kanis,et al.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.

[49]  J. Kanis,et al.  Development and use of FRAX® in osteoporosis , 2010, Osteoporosis International.

[50]  Jacques P. Brown,et al.  Bone turnover markers in the management of postmenopausal osteoporosis. , 2009, Clinical biochemistry.

[51]  Eugene McCloskey,et al.  FRAX and its applications to clinical practice. , 2009, Bone.

[52]  L. Bastian,et al.  Does this woman have osteoporosis? , 2004, JAMA.

[53]  W. Willett,et al.  Walking and leisure-time activity and risk of hip fracture in postmenopausal women. , 2002, JAMA.

[54]  M. Nevitt,et al.  Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  C. Shaw.  An epidemiologic study of osteoporosis in Taiwan. , 1993, Annals of epidemiology.